Enanta Pharmaceuticals Inc (NASDAQ:ENTA) shares, rose in value on Wednesday, June 18, with the stock price up by 2.55% to the previous day’s close as strong demand from buyers drove the stock to $7.23.
Actively observing the price movement in the last trading, the stock closed the session at $7.05, falling within a range of $6.87 and $7.305. The value of beta (5-year monthly) was 0.772. Referring to stock’s 52-week performance, its high was $17.24, and the low was $4.09. On the whole, ENTA has fluctuated by 21.31% over the past month.
With the market capitalization of Enanta Pharmaceuticals Inc currently standing at about $154.55 million, investors are eagerly awaiting this quarter’s results, scheduled for on 2025-May-12.
Technical indicators serve as essential tools for traders, offering insights into market sentiment and potential price movements. We see that ENTA’s technical picture suggests that short-term indicators denote the stock is a 50% Buy on average. However, medium-term indicators have put the stock in the category of 50% Sell while long-term indicators on average have been pointing out that it is a Hold.
The stock’s technical analysis shows that the price of ENTA currently trading nearly 6.40% and 22.02% away from the simple moving averages for 20 and 50 days respectively. The Relative Strength Index (RSI, 14) currently indicates a reading of 59.30, while the 7-day volatility ratio is showing 2.91% which for the 30-day chart, stands at 4.45%. Furthermore, Enanta Pharmaceuticals Inc (ENTA)’s beta value is 0.77, and its average true range (ATR) is 0.47.
A comparison of Enanta Pharmaceuticals Inc (ENTA) with its peers suggests the former has fared considerably weaker in the market. ENTA showed an intraday change of 2.55% in last session, and over the past year, it shrunk by -43.69%%.
Data on historical trading for Enanta Pharmaceuticals Inc (NASDAQ:ENTA) indicates that the trading volumes over the past 10 days have averaged 0.21 and over the past 3 months, they’ve averaged 193.29K. According to company’s latest data on outstanding shares, there are 21.38 million shares outstanding.
Nearly 7.09% of Enanta Pharmaceuticals Inc’s shares belong to company insiders and institutional investors own 87.45% of the company’s shares. The data on short interest also indicates that stock shorts accounted for 2.72 million shares as on 2025-05-30, resulting in a short ratio of 22.35. According to the data, the short interest in Enanta Pharmaceuticals Inc (ENTA) stood at 1353.00 of shares outstanding as of 2025-05-30; the number of short shares registered in 2025-04-30 reached 2.96 million. The stock has risen by 25.74% since the beginning of the year, thereby showing the potential of a further growth. This could raise investors’ confidence to be optimistic about the ENTA stock heading into the next quarter.
